Exact Sciences (EXAS) New Deal with Pfizer a 'Win-Win' - Cowen
Tweet Send to a Friend
Cowen analyst Doug Schenkel reiterated an Outperform rating and $135.00 price target on Exact Sciences (NASDAQ: EXAS) calling the new ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
